Meet Monk Fruit Sweetener, now made in the United States.
Made by Manus®
Monk Fruit Sweetener
For the first time ever, monk fruit sweetener is being manufactured at commercial scale in the United States – right here at our biomanufacturing facility in Augusta, Georgia.
We have reimagined a scarce, crop-dependent ingredient into a more reliable, scalable, and sustainable sweetening solution for global food and beverage brands. By moving beyond traditional supply constraints and overseas sourcing, we are helping shape a more resilient – and more delicious – future for sweetness.
Thought leadership
The search is over.
Manus’ Founder and CEO on the end of the synthetic era – and what scale makes possible now.
Saccharin in 1879. Sucralose in 1998. For 140 years, every sweetener has solved part of the puzzle – calorie-free, sugar-like, natural, scalable – but never all of it at once. In this white paper, Dr. Ajikumar "Aji" Parayil argues the missing piece was never another molecule. It was a way to make the ones we already have, at scale. A clear-eyed account of what synthetic chemistry could never solve – and what biomanufacturing finally can.
Applications
Monk Fruit Sweetener can be incorporated into a wide variety of food and beverage applications, delivering a clean, sugar-like taste and next-generation sugar reduction at scale.
Dairy
Sugar reduction for yogurt and cultured dairy.
Nutritional
High-intensity sweetness for protein powders and ready-to-drink.
Beverages
Dissolves completely, hot or cold – from the cup to the dispenser.
Speak to an expert
Schedule time with Sai Prakash Chaturvedula, Senior Vice President – Commercial, to learn more about Monk Fruit Sweetener
Yume M Stevia Sweetener
Explore also our premium stevia sweetener that forgoes many of the risks associated with traditional stevia agriculture. Without compromising flavor or performance.
Learn more
Made by Manus®.
Brought to you by Tate & Lyle.
Newsletter
Get The BioAlternatives Brief
Welcome to The BioAlternatives Brief, built for leaders navigating the shift to bioalternatives by connecting market movement, technical progress, and what it means for everything that comes next.
Get the Brief